Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
70.23
-1.15 (-1.61%)
At close: May 9, 2025, 4:00 PM
69.00
-1.23 (-1.75%)
After-hours: May 9, 2025, 6:06 PM EDT

Company Description

Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.

It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing’s syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.

The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial.

In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis.

The company was incorporated in 1998 and is headquartered in Redwood City, California.

Corcept Therapeutics Incorporated
Corcept Therapeutics logo
Country United States
Founded 1998
Industry Biotechnology
Sector Healthcare
Employees 500
CEO Joseph Belanoff

Contact Details

Address:
101 Redwood Shores Parkway
Redwood City, California 94065
United States
Phone 650 327 3270
Website corcept.com

Stock Details

Ticker Symbol CORT
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001088856
CUSIP Number 218352102
ISIN Number US2183521028
Employer ID 77-0487658
SIC Code 2834

Key Executives

Name Position
Dr. Joseph K. Belanoff M.D. Co-Founder, President, Chief Executive Officer and Director
Atabak Mokari Chief Financial Officer and Treasurer
Sean Maduck President of Endocrinology
Dr. William Guyer Pharm.D. Chief Development Officer
Gary Charles Robb J.D. Chief Business Officer and Secretary
Joseph Douglas Lyon Chief Accounting and Technology Officer
Dr. Hazel Hunt Ph.D. Chief Scientific Officer
Amy Flood Chief Human Resources and Communications Officer
Monica Tellado President of Emerging Markets
Roberto W. Vieira President of Oncology

Latest SEC Filings

Date Type Title
May 5, 2025 10-Q Quarterly Report
May 5, 2025 8-K Current Report
May 2, 2025 144 Filing
May 2, 2025 144 Filing
May 1, 2025 144 Filing
Apr 25, 2025 DEF 14A Other definitive proxy statements
Apr 23, 2025 SCHEDULE 13G/A Filing
Apr 10, 2025 144 Filing
Apr 1, 2025 144 Filing
Apr 1, 2025 144 Filing